Brief: Novo Nordisk Says People With Type 2 Diabetes Who Were Increased To Semaglutide 2 Mg Were more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide
06/06/2026 14:07
BRIEF-Novo Nordisk Says People With Type 2 Diabetes Who Were Increased To Semaglutide 2 Mg Were more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide June 6 (Reuters) - Novo Nordisk A/S NOVOb.CO:
PEOPLE WITH TYPE 2 DIABETES WHO WERE INCREASED TO SEMAGLUTIDE 2 MG WERE AS LIKELY TO ACHIEVE AN HBA1C LESS THAN 7% AND MORE LIKELY TO ACHIEVE GREATER THAN 5% WEIGHT LOSS THAN THOSE WHO WERE SWITCHED TO TIRZEPATIDE, IN REAL-WORLD DATA
NOVO NORDISK - SEMAGLUTIDE 2 MG MATCHES TIRZEPATIDE FOR HBA1C <7% AND OUTPERFORMS FOR ≥5% WEIGHT LOSS AT 1 YEAR
74.7% ON SEMAGLUTIDE 2 MG AND 75.1% ON TIRZEPATIDE ACHIEVE HBA1C <7% AT 1 YEAR
NOVO NORDISK - 60.5% ON SEMAGLUTIDE 2 MG AND 55.3% ON TIRZEPATIDE ACHIEVE ≥5% WEIGHT LOSS AT 1 YEAR
Source text: ID:nPn3wl63Za
Further company coverage: [NOVOb.CO]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)